intravenous immunoglobulin (IVIG) marketUSD 14.9 billion in 2025USD 25.7 billion by 20337.0% CAGR from 2026 to 203345.9% in 2025The global was valued at and is expected to reach , expanding at a . The market is projected to increase from USD 16.0 billion in 2026. North America accounted for the largest revenue share at , while Asia Pacific is expected to register the fastest growth during the forecast period.

Rising incidences of autoimmune disorders, primary and secondary immunodeficiencies, and neurological diseases are strengthening demand for immunoglobulin-based therapies. Increasing disease awareness, improved diagnosis of immune disorders, advances in immunotherapy, and an aging population are also supporting market expansion.

Application and Distribution Trends

Immunodeficiency diseases: This application segment represented the largest revenue share, accounting for 19.5% of the market in 2025.
Hospital pharmacies: Hospital pharmacies led distribution channels with a 57.1% revenue share in 2025.

Regional Market Landscape

North AmericaAsia Pacific was the leading regional market in 2025, capturing 45.9% of global revenue. The U.S. held the largest country-level market share during the same year. is anticipated to record the highest CAGR from 2026 to 2033, supported by increasing healthcare demand and improving diagnosis and treatment access.

Market Size & Forecast

2025 market size: USD 14.9 billion
2026 estimated market size: USD 16.0 billion
2033 projected market size: USD 25.7 billion
2026–2033 CAGR: 7.0%
Leading region in 2025: North America, with 45.9% revenue share

Download a free sample report or claim your copy of this full market intelligence report

What Is Driving the IVIG Market?

Intravenous immunoglobulin remains an important treatment option for primary and acquired immunodeficiency diseases. Growing awareness of immune-related disorders and advances in immunotherapy are increasing diagnosis and treatment rates. An aging population is also contributing to demand because older individuals are more susceptible to several immune-related and chronic conditions.

IVIG demand is further supported by its use in neurological and autoimmune conditions. For patients requiring immunoglobulin replacement, the therapy can remain an essential component of long-term disease management. Improvements in plasma collection, processing, and manufacturing technologies are also helping industry participants respond to rising demand.

Undiagnosed Immunodeficiency Creates Long-Term Demand

According to NCBI data cited in the study, more than 6 million people worldwide were affected by primary immunodeficiencies in 2020, while an estimated 70% to 90% remained undiagnosed. More than 430 types of primary immunodeficiencies have been identified. These disorders can increase susceptibility to infections and may also be associated with autoinflammation, autoimmunity, allergies, and malignancies.

Greater awareness and improvements in diagnosis could therefore expand the number of patients identified as candidates for immunoglobulin therapy. Combined with advances in plasma-derived product manufacturing, these developments are expected to support sustained IVIG market growth.

High Treatment Costs Remain a Market Constraint

Despite strong therapeutic demand, the high cost of IVIG treatment remains a significant barrier to broader adoption. Infusions are commonly administered every three to four weeks, potentially requiring 12 to 16 sessions annually. The estimated IVIG price is approximately USD 73.89 per gram, while total treatment costs can reach USD 10,000 or more depending on disease severity.

Immunoglobulin replacement therapy may continue for six months or longer, increasing the financial burden for patients and healthcare systems. The ABIM Foundation has reported annual IgG treatment costs exceeding USD 30,000, highlighting affordability and reimbursement as important considerations for future market expansion.

Looking for more in-depth data focusing on specific segments or regions? Get this report customized with inclusion of custom data sets to suit your exact business needs.

Market Dynamics

The IVIG market is shaped by the rising prevalence of primary immunodeficiency disorders, autoimmune diseases, and neurological conditions requiring immunoglobulin-based therapies. Increasing disease awareness, improved diagnosis, and broader use of IVIG across hospitals and specialty care centers are supporting demand.

On the supply side, market growth is closely linked to the availability of human plasma, which serves as the raw material for IVIG products. Plasma collection and processing capacity therefore remain important factors influencing supply. Market participants continue to expand manufacturing capabilities and plasma collection networks to address increasing treatment requirements.

Regulatory approvals are also influencing product availability and competition. For example, in June 2025, Takeda received U.S. FDA approval for Gammagard Liquid ERC, a ready-to-use low-IgA immunoglobulin therapy for primary humoral immunodeficiency. The approval expanded Takeda's immunoglobulin portfolio and supported the availability of plasma-derived treatment options for eligible patients.

In addition, reimbursement policies, regulatory requirements, healthcare expenditure, and treatment accessibility continue to influence the adoption of IVIG therapies across healthcare facilities.

Explore the full list of profiled companies operating in this market with recent strategic initiatives

Key Companies in the Intravenous Immunoglobulin Market

The study profiles major participants operating in the global IVIG market, including:

Biotest AG
Baxter
Octapharma AG
LFB
Grifols SA
CSL
China Biologics Products Inc.
Kedrion
BDI Pharma Inc.

Explore our dedicated business services:

Prism AI: Market Intelligence with Cited Research- Ask questions in plain language and get insights drawn from Grand View Research's entire research library, with sources cited. Create your free account today.

U.S. Healthcare Facility Mapping & Intelligence Platform: Sign up TodayGet facility-level intelligence to guide smarter decisions.

The Role of Biosimilar Alternatives in Immunoglobulin Treatment Choices

The global intravenous immunoglobulin (IVIG) market was valued at USD 14.9 billion in 2025 and is expected to reach USD 25.7 billion by 2033, expanding at a 7.0